Download Thank You!

Thank you for downloading!

Check out more content that may interest you and follow us on social media

  • The latest from Median

    Median Technologies has officially commenced operations with all investigator sites participating in the pivotal validation plan for its iBiopsy® Lung Cancer Screening (LCS) AI/ML tech-based CADe/CADx Software as Medical Device (SaMD).
    Median reports today its business indicators for the first half of 2023 for the iCRO activity and the iBiopsy® activity. The Company also announces the first step of ths refinancing plan.
    The study showed that CT-based radiomics can accurately predict the histopathological subtype of NSCLC patients, offering a less invasive and more cost-effective alternative to traditional tissue analysis methods.
    AI-powered medical image analysis has the potential to serve as predictive biomarkers for guiding targeted therapies in the future
    Median will be exhibiting at the ESMO Congress on October 20 – 24 in Madrid. Happy to see you there at IFEMA Madrid, Hall 5, booth #522!

    Conferences

    20 – 24 October, 2023

    ESMO 2023

    Median will be exhibiting at the ESMO Congress on October 20 – 24 in Madrid. Happy to see you there at IFEMA Madrid, Hall 5, booth #522!